Dr. Muhammed Majeed of Sami Labs, Sushil Suri of Morepen Laboratories,Bafna Mahaveer Chand of Bafna Pharmaceuticals, Davuluri Rama Mohan Rao of Neuland Laboratories, Varaprasad Reddy of Shantha Biotechnics & Jayesh Pannalal Choksi of Gufic Biosciences are in the race for Pharma Leaders Transformational Business Leader of the Decade 2018

Dr. Muhammed Majeed of Sami Labs, Sushil Suri of Morepen Laboratories,Bafna Mahaveer Chand of Bafna Pharmaceuticals, Davuluri Rama Mohan Rao of Neuland Laboratories, Varaprasad Reddy of Shantha Biotechnics & Jayesh Pannalal Choksi of Gufic Biosciences are in the race for Pharma Leaders Transformational Business Leader of the Decade 2018
Pharma Leaders Transformational Business Leader of the Decade 2018 Nominees
1. Dr. Muhammed Majeed, Founder & Managing Director, Sami Labs Limited
2. Mr. Sushil Suri,Chairman & Managing Director,Morepen Laboratories Limited
3. Mr. Bafna Mahaveer Chand,Chairman & Managing Director, Bafna Pharmaceuticals Limited
4. Dr. Davuluri Rama Mohan Rao,CMD, Neuland Laboratories Ltd.
5. Mr. Varaprasad Reddy,Founder & Non-Executive Chairman,Shantha Biotechnics Pvt Ltd
6. Mr. Jayesh Pannalal Choksi, CMD, Gufic Biosciences Limited

The Indian pharmaceutical market (IPM) grew at 9.7 percent in the second quarter ended September, according to market research firm AIOCD-AWACS, displaying pre-GST level growth rate. IPM growth rate had slumped to 1 percent in the same period previous year due to the disruption caused by GST implementation. IPM grew close to 10 percent in the first half of FY19, returning to the 10 percent growth of FY17. The growth had dropped to 6.1 percent in the run-up to GST and its subsequent implementation. “Third quarter 2018 posted the highest growth as compared to last four quarters, highest Incremental value added on a quarterly basis since Q4 2016,” said AIOCD-AWACS in a statement. For September, IPM grew at 7.5 percent, slower than August due to the decline in the growth of medicines to treat dermatology and gastrointestinal segment.
The industry grew at the fastest past of 12.7 percent in July. The IPM reported sales of ₹11,324 crore for September. The IPM stood at ₹1.26 lakh crore for the moving annual total (MAT) ended September. The acute segment led by anti-infectives grew at 9.9 percent and respiratory saw 11 percent growth in September signaling the onset of a seasonal factor. The fixed-dose combination (FDC) related market declined 6.6 percent while the FDCs not under ban saw growth of 7.6 percent. Single molecules grew at 7.6 percent for the month of September. The government banned hundreds of FDCs citing lack of therapeutic justification.
The price controlled National List of Essential Medicines (NLEM) 2013 molecules market showed growth at 3.8 percent whereas the non-NLEM market grew at 7.9 percent. Volumes in September were stagnant at 0.1 percent while the price growth stood at 4.8 percent. The newly-introduced drugs that mostly do not fall under price-controlled category rose 2.5 percent. Among the top 10 Indian drug makers, Mankind had the highest growth at 13.4 percent in September followed by Lupin at 11 percent, Intas at 10.6 percent, Torrent Pharma at 5.9 percent and Alkem 9.1 percent. Market leader Sun Pharma grew at 4.7 percent, Cipla 9.1 percent and Cadila Healthcare 5 percent. In MNC pack Abbott grew 6.1 percent and GSK 2.72 percent. The top 10 drug makers contribute about 42.6 percent to the IPM
The Indian pharmaceutical market is dominated by ‘branded generics’ limiting generic-induced price competition, when globally generic drugs are perceived as key competitive force against the patent-expired brand name drugs marketed at monopoly prices, a policy note issued by Competition Commission of India (CCI). The fair trade watchdog pointed out that the branded generic drugs enjoy a price premium owing to perceived quality assurance that comes with the brand name. Quality consideration may be a reason behind the prescription of branded generics by doctors. However, it is also equally possible that the brand proliferation is to introduce artificial product differentiation in the market, offering no therapeutic difference but allowing firms to extract rents.

Pharma Leaders Awards also known as Pharmaleaders Power Brand recognizes Asia’s top health-care industry leaders, innovators, and companies. This awards-recognition event has been honoring those individuals and/or organizations since 1999 who have a significant impact on the quality of health care and services in our communities. An independent group of judges use a point system to assign values in all different leadership categories. Winners are selected based on the highest total scores from the Pharmaleaders/Network 7 Media Group judges. Pharma Leaders Awards and the judges reserve the right to present multiple or no awards in any category. This distinctive award honors healthcare organizations that demonstrate excellence in overall leadership & management in adopting best practice solutions in Healthcare Innovations! .Pharma Leaders Awards recognize the value of innovation & excellence in healthcare leadership and strives to reward campaigns which have an edge by being unique, instinctive, and authentic. Network 7 Media Group Advisory Board is represented by prominent health care professionals whose respected reputations and knowledge of the industry continually generates prominence for the competition, while expanding the international reach of the Pharma Leaders Awards also known as Pharmaleaders power brands.